Home/Filings/4/0001209191-21-050040
4//SEC Filing

LUDLAM WILLIAM 4

Accession 0001209191-21-050040

CIK 0001339469other

Filed

Aug 4, 8:00 PM ET

Accepted

Aug 5, 6:05 PM ET

Size

31.4 KB

Accession

0001209191-21-050040

Insider Transaction Report

Form 4
Period: 2021-08-05
LUDLAM WILLIAM
See Remarks
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2021-08-0545,9160 total
    Exercise: $28.40Common Stock (45,916 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2021-08-059690 total
    Exercise: $9.93Common Stock (969 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2021-08-0574,9970 total
    Exercise: $2.60Common Stock (74,997 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2021-08-0518,1890 total
    Exercise: $1.52Common Stock (18,189 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2021-08-0565,0000 total
    Exercise: $4.57Common Stock (65,000 underlying)
  • Disposition to Issuer

    Common Stock

    2021-08-0511,7990 total
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2021-08-0514,0840 total
    Exercise: $28.40Common Stock (14,084 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2021-08-0570,0000 total
    Exercise: $3.75Common Stock (72,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2021-08-0514,5310 total
    Exercise: $9.93Common Stock (14,531 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2021-08-0525,0030 total
    Exercise: $2.60Common Stock (25,003 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2021-08-0552,0110 total
    Exercise: $1.52Common Stock (52,011 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2021-08-05120,0000 total
    Exercise: $4.55Common Stock (120,000 underlying)
Footnotes (3)
  • [F1]This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time").
  • [F2]At the Effective Time, each share of common stock of the Company (each, a "Share") (excluding any Shares held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 0.396 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing five ordinary shares of Parent.
  • [F3]At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an "Assumed Stock Option") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.

Issuer

CHIASMA, INC

CIK 0001339469

Entity typeother

Related Parties

1
  • filerCIK 0001736280

Filing Metadata

Form type
4
Filed
Aug 4, 8:00 PM ET
Accepted
Aug 5, 6:05 PM ET
Size
31.4 KB